[1. S. M. Reppert, D. R. Weaver and C. Godson, Melatonin receptors step into the light: cloning and classification of subtypes, Trends Pharmacol. Sci.17 (1996) 100–102; https://doi.org/10.1016/0165-6147(96)10005-510.1016/0165-6147(96)10005-5]Search in Google Scholar
[2. E. Mills, P. Wu, D. Seely and G. Guyatt, Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis, J. Pineal. Res.39 (2005) 360–366; https://doi.org/10.1111/j.1600-079X.2005.00258.x10.1111/j.1600-079X.2005.00258.x16207291]Search in Google Scholar
[3. S. Malhotra, G. Sawhney and P. Pandhi, The therapeutic potential of melatonin: a review of the science, MedGenMed.6 (2004) 46; https://doi.org/10.0000/ncbi.nlm.nih.gov/PMC1395802]Search in Google Scholar
[4. M. L. Dubocovich, P. Delagrange, D. N. Krause, D. Sugden, D. P. Cardinali and J. Olcese, International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein coupled melatonin receptors, Pharmacol. Rev.62 (2010) 343–380; https://doi.org/10.1124/pr.110.00283210.1124/pr.110.002832296490120605968]Search in Google Scholar
[5. L. M. Hack, S. W. Lockley, J. Arendt and D. J. Skene, The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects, J. Biol. Rhythms.18 (2003) 420–429; https://doi.org/10.1177/074873040325679610.1177/074873040325679614582858]Search in Google Scholar
[6. A. J. Lewy, J. N. Rough, J. B. Songer, N. Mishra, K. Yuhas and J. S. Emens, The phase shift hypothesis for the circadian component of winter depression, Dialogues Clin. Neurosci.9 (2007) 291–300.10.31887/DCNS.2007.9.3/alewy]Search in Google Scholar
[7. J. Arendt and D. J. Skene, Melatonin as a chronobiotic, Sleep Med. Rev.9 (2005) 25–39; https://doi.org/10.1016/j.smrv.2004.05.00210.1016/j.smrv.2004.05.00215649736]Search in Google Scholar
[8. R. Sharma, C. R. McMillan, C. C. Ten and L. P. Niles, Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson’s disease, Brain Res.1068 (2006) 230–236; https://doi.org/10.1016/j.brainres.2005.10.08410.1016/j.brainres.2005.10.08416375867]Search in Google Scholar
[9. M. Olcese, C. Cao, T. Mori, M. B. Mamcarz, A. Maxwell, M. J. Runfelt, C. Wang, X. Lin, G. Zhang and G. W. Arendash, Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease, J. Pineal Res.47 (2009) 82–96; https://doi.org/10.1111/j.1600-079X.2009.00692.x10.1111/j.1600-079X.2009.00692.x19538338]Search in Google Scholar
[10. S. G. Grant, M. A. Melan, J. J. Latimer and P. A. Witt-Enderby, Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives, Expert Rev. Mol. Med.11 (2009) e5. https://doi.org/10.1017/S146239940900098210.1017/S1462399409000982430173519193248]Search in Google Scholar
[11. S. Sibel, Melatonin and synthetic analogs as antioxidants, Curr. Drug Deliv. 10 (2013) 71–75; https://doi.org/10.2174/156720181131001001310.2174/156720181131001001322998047]Search in Google Scholar
[12. M. Vlachou and A. Siamidi, Melatonin Modified Release Formulations, in Melatonin – Molecular Biology, Clinical and Pharmaceutical Approaches (Ed. C. M. Dragoi); http://dx.doi.org/10.5772/intechopen.7833710.5772/intechopen.78337]Search in Google Scholar
[13. M. Vlachou, A. Siamidi, I. Pareli, A. Zampakola and S. Konstantinidou, An account of modified release of melatonin from compression-coated, uncoated and bilayer tablets, J. Pharm. Pharm. Scien.1 (2016) 10–14; https://doi.org/10.24218/vjpps.2016.1910.24218/vjpps.2016.19]Search in Google Scholar
[14. M. Vlachou, A. Siamidi, S. Konstantinidou and Y. Dotsikas, Optimization of controlled release matrix formulation of melatonin via experimental design, J. Pharm. Drug Deliv. Res.5 (2016) 1–5; https://doi.org/10.4172/2325-9604.100015910.4172/2325-9604.1000159]Search in Google Scholar
[15. A. Zampakola, A. Siamidi, N. Pippa, C. Demetzos and M. Vlachou, Chronobiotic hormone melatonin: comparative in vitro release studies from matrix tablets and liposomal formulations, Lett. Drug Des. Discov.14 (2017) 476–480; https://doi.org/10.2174/157018081366616100616224610.2174/1570180813666161006162246]Search in Google Scholar
[16. M. Vlachou, M. Papamichael, A. Siamidi, I. Fragouli, P. A. Afroudakis, R. Kompogennitaki and Y. Dotsikas, Comparative in vitro controlled release studies on the chronobiotic hormone melatonin from cyclodextrins-containing matrices and cyclodextrin: melatonin complexes, Int. J. Mol. Sci.18 (2017) 1641; https://doi.org/10.3390/ijms1808164110.3390/ijms18081641557803128788064]Search in Google Scholar
[17. M. Vlachou, K. Tragou, A. Siamidi, S. Kikionis, A. L. Chatzianagnostou, A. Mitsopoulos, E. Ioannou, V. Roussis and A. Tsotinis, Modified in vitro release of the chronobiotic hormone melatonin from matrix tablets based on the marine sulfated polysaccharide ulvan, J. Drug Deliv. Sci. Technol.44 (2018) 41–48; https://doi.org/10.1016/j.jddst.2017.11.01910.1016/j.jddst.2017.11.019]Search in Google Scholar
[18. M. Vlachou, S. Kikionis, A. Siamidi, K. Tragou, E. Ioannou, V. Roussis and A. Tsotinis, Modified in vitro release of melatonin loaded in nanofibrous electrospun mats incorporated into mono-layered and three-layered tablets, J. Pharm. Sci.108 (2019) 970–976; https://doi.org/10.1016/j.xphs.2018.09.03510.1016/j.xphs.2018.09.03530312723]Search in Google Scholar
[19. M. Vlachou, S. Kikionis, A. Siamidi, K. Tragou, S. Kapoti, E. Ioannou, V. Roussis and A. Tsotinis, Fabrication and characterization of electrospun nanofibers for the modified release of the chronobiotic hormone melatonin, Curr. Drug Deliv. 16 (2019) 79–85; https://doi.org/10.2174/156720181566618091409570110.2174/1567201815666180914095701634015330215335]Search in Google Scholar
[20. M. Vlachou, G. Stavrou, A. Siamidi, S. Flitouri, V. Ioannidou and S. Mavrokordopoulos, N-Acetylserotonin vs. melatonin. In vitro controlled release from hydrophilic matrix tablets, Lett. Drug Des. Discov.16 (2019) 347–352; https://doi.org/10.2174/157018081566618040412551910.2174/1570180815666180404125519]Search in Google Scholar
[21. B. Girgin, O. Korkmaz, R. Yavaşer and A. A. Karagözler, Production and drug release assessment of melatonin-loaded alginate/gum arabic beads, JOTCSA3 (2016) 205–216; https://doi.org/10.18596/jotcsa.3088010.18596/jotcsa.30880]Search in Google Scholar
[22. O. Şanlı, N. Ay and N. Işıklan, Release characteristics of diclofenac sodium from poly (vinyl alcohol)/sodium alginate and poly (vinyl alcohol)-grafted-poly (acrylamide)/sodium alginate blend beads, Eur. J. Pharm. Biopharm.65 (2007) 204–214; https://doi.org/10.1016/j.ejpb.2006.08.00410.1016/j.ejpb.2006.08.004]Search in Google Scholar
[23. N. Pippa, N. Bouropoulos, S. Pispas, C. Demetzos and A. Papalois, Chapter 3. Hydrogels as intelligent drug delivery systems in drug delivery, Nanosystems 2019; 59–91; https://doi.org/10.1201/9780429490545-310.1201/9780429490545-3]Search in Google Scholar
[24. Pharmacopeia US, USP 29-NF24, Rockville, 2005.]Search in Google Scholar
[25. G. Pasparakis and N. Bouropoulos, Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate–chitosan beads, Int. J. Pharm.323 (2006) 34–42; https://doi.org/10.1016/j.ijpharm.2006.05.05410.1016/j.ijpharm.2006.05.054]Search in Google Scholar
[26. I. Colinet, V. Dulong, G. Mocanu, L. Picton and D. Le Cerf, New amphiphilic and pH-sensitive hydrogel for controlled release of a model poorly water-soluble drug, Eur. J. Pharm. Biopharm.73 (2009) 345–350; https://doi.org/10.1016/j.ejpb.2009.07.00810.1016/j.ejpb.2009.07.008]Search in Google Scholar
[27. N. Pippa, T. Sentoukas, S. Pispas, C. Demetzos, A. Papalois and N. Bouropoulos, pH-responsive polymeric nanoassemblies encapsulated into alginate beads: morphological characterization and swelling studies, J. Pol. Res.25 (2018) 117; https://doi.org/10.1007/s10965-018-1519-110.1007/s10965-018-1519-1]Search in Google Scholar
[28. J. Siepmann and N. A. Peppas, Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC), Adv. Drug Deliv. Rev.48 (2001) 139–57; https://doi.org/10.1016/S0169-409X(01)00112-010.1016/S0169-409X(01)00112-0]Search in Google Scholar
[29. P. L. Ritger and N. A. Peppas, A simple equation for description of solute release II. Fickian and anomalous release from swellable devices, J. Control. Release5 (1987) 37–42; https://doi.org/10.1016/0168-3659(87)90035-610.1016/0168-3659(87)90035-6]Search in Google Scholar
[30. Ν. Η. Anderson, Μ. Bauer, Ν. Boussac, Ρ. R. Khan-Malek, P. Munden and M. Sardaro, An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles, J. Pharm. Biomed. Anal. 17 (1998) 811–822; https://doi.org/10.1016/s0731-7085(98)00011-910.1016/S0731-7085(98)00011-9]Search in Google Scholar
[31. J. L. Shamshina, G. Gurau, L. E. Block, L. K. Hansen, C. Dingee, A. Walters and R. D. Rogers, Chitin--calcium alginate composite fibers for wound care dressings spun from ionic liquid solution, J. Mater. Chem. B2 (2014) 3924; http://dx.doi.org/10.1039/C4TB00329B10.1039/C4TB00329B]Search in Google Scholar
[32. S. Soni, A. Verma and V. Ram, Evaluation of chitosan-hydroxy propyl methyl cellulose as a single unit hydrodynamically balanced sustained release matrices for stomach specific delivery of piroxicam, MOJ Bioequiv. 2 (2016) 14; http://dx.doi.org/10.4172/0975-0851.C1.02510.4172/0975-0851.C1.025]Search in Google Scholar
[33. T. H. C. Salles, C. B. Lombello and M. A. d’ Ávila, Electrospinning of gelatin/poly (vinyl pyrrolidone) blends from water/acetic acid solutions, Materials Research18 (2015) 509–518; http://dx.doi.org/10.1590/1516-1439.31011410.1590/1516-1439.310114]Search in Google Scholar
[34. Y. Listiohadi, J. A. Hourigan, R. W. Sleigh and R. J. Steele, Thermal analysis of amorphous lactose and α-lactose monohydrate, Dairy Sci. Technol.89 (2009) 43–67; https://doi.org/10.1051/dst:200802710.1051/dst:2008027]Search in Google Scholar
[35. A. S. Hoffman Hydrogels for biomedical applications, Adv. Drug Deliv. Rev.43 (2002) 3–12; https://doi.org/10.1016/j.addr.2012.09.01010.1016/j.addr.2012.09.010]Search in Google Scholar
[36. S. P. Chaudhari and R. H. Dave, Investigating the effect of molecular weight of polyvinylpyrrolidone and hydroxypropyl methyl cellulose as potential antiprecipitants on supersaturated drug solutions and formulations using weakly acidic drug: indomethacin, IJPSR7 (2016) 3931–3948; https://doi.org/10.13040/IJPSR.0975-8232.7(10).3931-4810.13040/IJPSR.0975-8232.7(10).3931-48]Search in Google Scholar
[37. A. Körner, L. Piculell, F. Iselau, B. Wittgren and A. Larsson, Influence of different polymer types on the overall release mechanism in hydrophilic matrix tablets, Molecules14 (2009) 2699–2716; https://doi.org/10.3390/molecules1408269910.3390/molecules14082699625537619701117]Search in Google Scholar
[38. M. Vlachou, A. Siamidi and E. Geraniou, Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets, Acta Pharm.70 (2020) 49–61; https://doi.org/10.2478/acph-2020-001010.2478/acph-2020-001031677367]Search in Google Scholar